Status:
TERMINATED
SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Smith-Lemli-Opitz Syndrome
Eligibility:
All Genders
1-89 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if simvastatin improves development and behavior in patients with Smith Lemli-Opitz syndrome (SLOS) receiving dietary cholesterol supplementation.
Detailed Description
Patients with SLOS receiving dietary cholesterol supplementation are given simvastatin, a drug that decreases the activity/expression of HMG-CoA reductase, an enzyme that controls the first step of th...
Eligibility Criteria
Inclusion
- Male or female over 1 years old
- Subject has confirmed diagnosis of Smith-Lemli-Opitz Syndrome
- Subject is currently receiving cholesterol supplementation
Exclusion
- Subjects too ill to travel to the study site
- Subjects who are unable to safely undergo study procedures
- Pregnant women
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01434745
Start Date
September 1 2011
End Date
October 1 2014
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health and Science University
Portland, Oregon, United States, 97239